Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
An article from
News roundup
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
Published July 1, 2026
Getty Images
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
BridgeBio adds $1B as it prepares three more drug launches
Roche drug sets new standard for KRAS-driven lung cancer
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and…
BridgeBio raises $1B via preferred equity from Sixth Street and KKR's HealthCare Royalty, stockpiling cash ahead of three drug…
Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its…
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout
